Karyopharm Therapeutics Inc.
KPTIQ· OTC
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2013 | Q2 2012 |
|---|---|---|
| Revenue | $133.00K | $533.00K |
| EPS Diluted | -$2.86 | -$2.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR